Tuesday, September 10, 2019 12:26:04 AM
NOTE in the Amarin section PRN stands for principal amount on convertible debt securities. They converted these to normal shares.
SHARES MARKET VALUE %PORTFOLIO CHANGE
ACADIA
2009: 24M / 37M = 64% SP = .80
2010: 14M / 38M = 36% SP = 1.25
Q4=175,588 $211,000 0.01 175,588
2011: 30M / 50M = 60% SP = 1.70
Q1=4,364,070 $7,070,000 0.29 4,188,482
Q2=4,364,420 $7,114,000 0.27 350
Q3=5,246,312 $5,666,000 0.24 881,892
2012: 31M / 53M = 58% SP = 1.51
Q4=15,621,812 $72,641,000 1.90 10,375,500
2013: 59M / 79M = 74% SP = 6.03
Q2=19,955,126 $362,186,000 7.16 4,333,314
2014: 90M / 93M = 96% SP = 23.30
Q1=20,481,442 $498,313,000 6.33 526,316
2015: 97M / 100M = 97% SP = 30.43
2016: 110M / 111M = 99% SP = 20.69
Q1=24,213,838 $677,019,000 7.14 3,732,396
Q2=24,516,738 $795,813,000 8.34 302,900
Q3=25,819,768 $821,327,000 7.45 1,303,030
2017: 119M / 122M = 97% SP = 34.59
Q4=27,228,338 $819,845,000 7.11 1,408,570
2018: 121M / 144M = 84% SP = 29.91
Q3=28,439,114 $590,396,000 3.89 1,210,776
Q4=39,713,842 $642,173,000 5.26 11,274,728
2019: 137M / 144M = 91% SP = 26.85
Q2=39,292,086 $1,050,277,000 7.14 -421,756
------------------------------------------------------------
AMARIN
2008: 4M / 22M = 18% SP = 2.74
2009: 32M / 42M = 76% SP = 1.15
2010: 66M / 100M = 66% SP = 8.88
2011: 95M / 130M = 73% SP = 8.16
2012: 78M / 144M = 54% SP = 8.52
2013: 47M / 167M = 28% SP = 1.83
2014: 50M / 174M = 28% SP = 1.02
2015: 47M / 181M = 25% SP = 2.08
Q1=2,205,710 $5,161,000 0.04 2,205,710
Q4=5,000,000(PRN) $4,480,000 0.04 5,000,000(PRN)
2016: 105M / 212M = 49% SP = 2.97
Q1=15,000,000(PRN) $12,103,000 0.13 10,000,000(PRN)
Q1=801,860 $1,227,000 0.01 -1,403,850
Q3=20,630,477 $65,811,000 0.60 19,828,617
Q4=25,052,380 $77,161,000 8.47 400,000
2017: 112M / 271M = 40% SP = 3.75
Q1=22,656,469 $72,501,000 0.59 486,960
Q2=22,669,509 $91,358,000 0.80 13,040
2018: 156M / 297M = 52% SP = 17.50
Q3=34,069,509 $554,311,000 3.65 11,400,000
Q4=42,592,824 $579,688,000 4.75 8,523,315
2019: 162M / 331M = 48% SP = 18.00
Q1=43,210,459 $897,049,000 5.74 617,635
Q2=41,544,288 $805,544,000 5.39 -1,666,171
Recent AMRN News
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 12:00:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 09:31:21 PM
- Amarin Chairman & CEO Issue Letter to Shareholders • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM